NTLA Latest Headlines

NTLA Surges as Phase 3 Data Shows 91% Reduction in Severe HAE Attacks—First One-Time Gene Therapy Candidate Nears FDA Submission

Market Chameleon (Mon, 15-Jun 11:48 AM)

Sell Rating Maintained on Clinical and Commercial Uncertainty; $9 Price Target Reaffirmed

at www.tipranks.com (Mon, 15-Jun 11:15 AM)

Wedbush Remains a Hold on Intellia Therapeutics (NTLA)

at www.tipranks.com (Mon, 15-Jun 10:16 AM)

Intellia Highlights Strong Phase 3 Lonvo-z HAE Results

at www.tipranks.com (Mon, 15-Jun 9:23 AM)

Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO)

at www.tipranks.com (Mon, 15-Jun 6:50 AM)

Intellia: Phase 3 HAELO Success Underpins Buy Rating as Analyst Maintains $25 Price Target

at www.tipranks.com (Mon, 15-Jun 6:35 AM)

Analysts’ Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR)

at www.tipranks.com (Mon, 15-Jun 5:11 AM)

Intellia Therapeutics Grants 47,150 RSUs to New Hires—What Does This Signal for Talent Strategy?

Market Chameleon (Mon, 8-Jun 7:53 AM)

Intellia’s Lonvo-z Cuts HAE Attacks by 87% in Phase 3; Cash Extends Runway Through 2028

Market Chameleon (Mon, 11-May 7:53 AM)

NTLA Announces Inducement Grants for 43 New Hires: What Does This Mean for Investors?

Market Chameleon (Mon, 4-May 7:07 AM)

NTLA Announces $180 Million Public Offering: What This Means for the Company’s Future

Market Chameleon (Wed, 29-Apr 7:36 AM)

Intellia's One-Time Gene Editing Therapy Achieves 87% Reduction in HAE Attacks: Global Milestone in Precision Medicine

Market Chameleon (Mon, 27-Apr 7:05 AM)

NTLA’s Lonvo-z Therapy Shows 96% Reduction in HAE Attacks: New Data Highlights Potential One-Time Treatment

Market Chameleon (Wed, 8-Apr 9:33 AM)